Amlexanox offers a range of benefits, including promoting weight loss, improving blood sugar levels, preventing bone loss, enhancing liver health, treating asthma, and effectively managing mouth ulcers, making it a versatile compound with potential therapeutic applications across multiple health conditions.
Amlexanox is a medication with fat-burning properties. It promotes fat loss by inhibiting the production of a specific enzyme in the body that is responsible for fat storage and inflammation. Amlexanox is known to protect against bone disorders and liver disease. It can also help treat certain medical conditions like asthma due to its anti-allergic properties. Furthermore, it has traditionally been used to treat ulcers due to its anti-inflammatory effects.
Amlexanox works by inhibiting the release of histamine and leukotrienes – both of which are involved in multiple mechanisms such as inflammation and allergic reaction. This medication also helps reduce weight loss by inhibiting TBK1 (TANK-binding kinase 1), an enzyme involved in fat storage and inflammation.
Amlexanox promotes reversible weight loss by influencing multiple mechanisms involved in metabolism and appetite regulation. It has been found to affect the expression of genes associated with fat storage and metabolism, contributing to reversible weight loss through reduced fat accumulation.
Moreover, amlexanox may influence energy expenditure through its potential effects on metabolic processes and energy homeostasis. Research suggests that amlexanox can impact energy expenditure by modulating certain signaling pathways within cells, potentially leading to increased energy expenditure. These actions on energy expenditure are of interest in understanding how amlexanox may contribute to metabolic regulation and overall metabolic health.
Additionally, amlexanox may suppress appetite and reduce food intake, which can further support reversible weight loss efforts. These combined effects make amlexanox a potential candidate for managing reversible weight loss and are of interest to those exploring amlexanox weight loss strategies.
The primary benefit of amlexanox is supported by a number of high-quality studies:
Amlexanox improves blood sugar levels primarily by targeting insulin resistance, a key factor in type 2 diabetes and metabolic disease. It enhances insulin sensitivity, allowing cells to respond more effectively to insulin signals and facilitating glucose uptake. This improved insulin sensitivity, promoted by amlexanox, results in better blood sugar control.
Additionally, amlexanox’s capacity to combat insulin resistance is a crucial aspect of its mechanism for enhancing blood sugar management. Through its effects on insulin resistance and improved insulin sensitivity, amlexanox contributes significantly to the regulation of blood sugar levels in individuals with type 2 diabetes and metabolic disease.
Studies show that amlexanox exerts its beneficial effects on blood sugar levels by targeting and mitigating insulin resistance, ultimately leading to improved insulin sensitivity in individuals with type 2 diabetes:
Amlexanox can prevent bone loss through multiple mechanisms by inhibiting the activity of osteoclasts, the cells responsible for breaking down bone tissue. By suppressing osteoclast function, amlexanox helps maintain bone density and prevent bone loss, making it a potential therapeutic option for conditions associated with bone deterioration such as osteoporosis. In addition, amlexanox may also be used as an anti-inflammatory agent for the treatment of bone disorders by inhibiting inflammation.
In one study, researchers investigated the effects of amlexanox on mice with bone loss caused by surgical removal of the ovaries.  Results showed that amlexanox inhibited the formation of osteoclasts, which are specialized cells that absorb and remove bone to allow the development of new bones and maintenance of bone strength. Moreover, amlexanox enhanced the production of bone-forming cells known as osteoblasts. These results suggest that amlexanox may be considered a new therapeutic candidate for bone disorders like osteoporosis and rheumatoid arthritis.
Amlexanox improves liver health by inhibiting inflammation and oxidative stress within the liver. It has been shown to inhibit certain inflammatory pathways and decrease the production of pro-inflammatory molecules. This anti-inflammatory effect helps protect liver cells from damage.
Additionally, amlexanox may enhance the body’s antioxidant defenses, further reducing oxidative stress in the liver. These combined actions contribute to improved liver health and make amlexanox a potential candidate for the management of liver conditions like non-alcoholic fatty liver disease (NAFLD) and inflammation-related liver disorders.
A number of studies suggest that amlexanox can protect against various types of liver disease:
Amlexanox treats asthma by inhibiting histamine release from mast cells, a key contributor to bronchoconstriction and airway inflammation in asthmatic individuals. By reducing histamine release, amlexanox helps to alleviate airway constriction and inflammation, thereby providing relief from asthma symptoms. This action makes amlexanox a potential candidate for asthma management, particularly in cases where histamine release from mast cells plays a significant role in symptom exacerbation.
Amlexanox also exhibits its potential in treating asthma as an anti-allergic compound, acting on multiple fronts to mitigate allergic responses. It operates as an anti-allergic compound by inhibiting histamine release, which is a hallmark of allergic reactions and a trigger for bronchoconstriction and airway inflammation in asthma patients.
Furthermore, this anti-allergic compound modulates other inflammatory pathways and immune responses, collectively contributing to its potential as an effective therapeutic option in managing asthma and reducing healing time.
Evidence supports the anti-asthma properties of amlexanox:
Amlexanox is a medication specifically formulated as an anti-inflammatory treatment to treat ulcers, particularly canker sores, also known as mouth ulcers. Canker sores are painful, small lesions that can develop inside the mouth, on the lips, or along the gumline.
Amlexanox functions as an anti-inflammatory medication by reducing the inflammation and irritation associated with canker sores. It does this by inhibiting the release of inflammatory mediators and suppressing the immune response in the affected area. By targeting the underlying inflammation, amlexanox provides effective relief from the discomfort and pain of canker sores.
Amlexanox is applied topically as a gel or ointment directly to the ulcerated area. This localized treatment helps speed up the healing time and reduces the duration of the canker sore. Amlexanox is a valuable option for individuals who suffer from recurrent canker sores, as it not only alleviates symptoms but also promotes faster healing time, improving overall oral health and comfort.
Studies show that amlexanox can safely and effectively treat ulcers such as canker sores:
Amlexanox side effects are very uncommon. There have been some side effects associated with the use of this drug wherein the patient had one of the issues listed below at some point while being on amlexanox. However, these side effects weren’t confirmed to be associated with the treatment and could have been a coincidence and not related to the use of amlexanox. Despite this, it was listed as a side effect associated with amlexanox even though these associated side effects are very uncommon.
Side effects associated with amlexanox may include the following:
Reilly SM, Abu-Odeh M, Ameka M, DeLuca JH, Naber MC, Dadpey B, Ebadat N, Gomez AV, Peng X, Poirier B, Walk E, Potthoff MJ, Saltiel AR. FGF21 is required for the metabolic benefits of IKKε/TBK1 inhibition. J Clin Invest. 2021 May 17;131(10):e145546. doi: 10.1172/JCI145546. PMID: 33822771; PMCID: PMC8121507.
Reilly SM, Chiang SH, Decker SJ, et al. An inhibitor of the protein kinases TBK1 and IKK-ɛ improves obesity-related metabolic dysfunctions in mice. Nat Med. 2013;19(3):313-321. doi:10.1038/nm.3082.
Oral EA, Reilly SM, Gomez AV, et al. Inhibition of IKKɛ and TBK1 Improves Glucose Control in a Subset of Patients with Type 2 Diabetes. Cell Metab. 2017;26(1):157-170.e7. doi:10.1016/j.cmet.2017.06.006.
Beyett TS, Gan X, Reilly SM, Chang L, Gomez AV, Saltiel AR, et al. Carboxylic Acid Derivatives of Amlexanox Display Enhanced Potency toward TBK1 and IKKε and Reveal Mechanisms for Selective Inhibition. Mol Pharmacol. 2018. October;94(4):1210–9. 10.1124/mol.118.112185.
He Q, Xia X, Yao K, Zeng J, Wang W, Wu Q, Tang R, Zou X. Amlexanox reversed non-alcoholic fatty liver disease through IKKε inhibition of hepatic stellate cell. Life Sci. 2019 Dec 15;239:117010. doi: 10.1016/j.lfs.2019.117010. Epub 2019 Oct 28. PMID: 31672578.
Zhang Y, Guan H, Li J, Fang Z, Chen W, Li F. Amlexanox Suppresses Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss. Sci Rep. 2015;5:13575. Published 2015 Sep 4. doi:10.1038/srep13575.
Qi J, Zhou Z, Lim CW, Kim JW, Kim B. Amlexanox ameliorates acetaminophen-induced acute liver injury by reducing oxidative stress in mice. Toxicol Appl Pharmacol. 2019 Dec 15;385:114767. doi: 10.1016/j.taap.2019.114767. Epub 2019 Nov 5. PMID: 31697998.
He Q, Zeng J, Yao K, Wang W, Wu Q, Tang R, Xia X, Zou X. Long-term subcutaneous injection of lipopolysaccharides and high-fat diet induced non-alcoholic fatty liver disease through IKKε/ NF-κB signaling. BiochemBiophys Res Commun. 2020 Nov 12;532(3):362-369. doi: 10.1016/j.bbrc.2020.08.036. Epub 2020 Aug 31. PMID: 32883523.
Zhou Z, Qi J, Lim CW, Kim JW, Kim B. Dual TBK1/IKKε inhibitor amlexanox mitigates palmitic acid-induced hepatotoxicity and lipoapoptosis in vitro. Toxicology. 2020 Nov;444:152579. doi: 10.1016/j.tox.2020.152579. Epub 2020 Sep 6. PMID: 32905826.
Zhou Z, Qi J, Zhao J, Lim CW, Kim JW, Kim B. Dual TBK1/IKKɛ inhibitor amlexanox attenuates the severity of hepatotoxin-induced liver fibrosis and biliary fibrosis in mice. J Cell Mol Med. 2020 Jan;24(2):1383-1398. doi: 10.1111/jcmm.14817. Epub 2019 Dec 10. PMID: 31821710; PMCID: PMC6991653.
Imokawa S, Satou A, Taniguchi M, Toyoshima M, Nakazawa K, Hayakawa H, Chida K. [Amlexanox has an acute bronchodilator effect in patients with aspirin-induced asthma (AIA)]. Nihon KyobuShikkan Gakkai Zasshi. 1993 Aug;31(8):976-82. Japanese. PMID: 8230896.
Inagaki M, Michimata H, Minato K, Sunaga Y, Kobayashi S, Tani G, Nakazawa T. [Inhibitory effect of amlexanox on asthmatic attacks in an aspirin sensitive asthmatic]. Nihon KyobuShikkan Gakkai Zasshi. 1992 Jun;30(6):1180-5. Japanese. PMID: 1507696.
Kohno S, Shimizu T, Mizuta J, Ogino K, Yamamura H, Ohata K, Kawai M, Shindo T, Wada H, Hitomi S. [Inhibitory effect of amlexanox (AA-673) on the immunological and non-immunological release of histamine or leukotrienes]. Arerugi. 1989 Nov;38(11):1236-45. Japanese. PMID: 2483310.
Urisu A, Iimi K, Kondo Y, Horiba F, Masuda S, Tsuruta M, Yazaki T, Torii S. [Inhibitory action amlexanox on interleukin-3-induced enhancement of histamine releasability of human leukocytes]. Arerugi. 1990 Oct;39(10):1448-54. Japanese. PMID: 1701989.
Ozasa K, Temizoz B, Kusakabe T, Kobari S, Momota M, Coban C, Ito S, Kobiyama K, Kuroda E, Ishii KJ. Cyclic GMP-AMP Triggers Asthma in an IL-33-Dependent Manner That Is Blocked by Amlexanox, a TBK1 Inhibitor. Front Immunol. 2019 Sep 26;10:2212. doi: 10.3389/fimmu.2019.02212. PMID: 31616416; PMCID: PMC6775192.
Iwama T, Komatsu N, Shikada K, Tanaka S. Reversing effect of anti-asthmatic drugs on bronchoconstriction induced by antigen challenge and histamine in anesthetized guinea pigs. Jpn J Pharmacol. 1992 Jan;58(1):19-25. doi: 10.1254/jjp.58.19. PMID: 1640659.
Makino E, Ohashi T, Takahashi H, Kato H, Ito Y, Nagai H, Koda A, Azuma H. Inhibitory effect of HSR-6071, a new anti-allergic agent, on experimental asthma in rats and guinea-pigs. J Pharm Pharmacol. 1990 Apr;42(4):236-41. doi: 10.1111/j.2042-7158.1990.tb05399.x. PMID: 1974289.
Costa R, Wagner DE, Doryab A, De Santis MM, Schorpp K, Rothenaigner I, Lehmann M, Baarsma HA, Liu X, Schmid O, Campillos M, Yildirim AÖ, Hadian K, Königshoff M. A drug screen with approved compounds identifies amlexanox as a novel Wnt/β-catenin activator inducing lung epithelial organoid formation. Br J Pharmacol. 2021 Jun 5. doi: 10.1111/bph.15581. Epub ahead of print. PMID: 34089180.
Ozasa K, Temizoz B, Kusakabe T, et al. Cyclic GMP-AMP Triggers Asthma in an IL-33-Dependent Manner That Is Blocked by Amlexanox, a TBK1 Inhibitor. Front Immunol. 2019;10:2212. Published 2019 Sep 26. doi:10.3389/fimmu.2019.02212.
Khandwala A, Van Inwegen RG, Alfano MC. 5% amlexanox oral paste, a new treatment for recurrent minor aphthous ulcers: I. Clinical demonstration of acceleration of healing and resolution of pain. Oral Surg Oral Med Oral Pathol Oral RadiolEndod. 1997 Feb;83(2):222-30. doi: 10.1016/s1079-2104(97)90009-3. PMID: 9117754.
Bhat S, Sujatha D. A clinical evaluation of 5% amlexanox oral paste in the treatment of minor recurrent aphthous ulcers and comparison with the placebo paste: a randomized, vehicle controlled, parallel, single center clinical trial. Indian J Dent Res. 2013 Sep-Oct;24(5):593-8. doi: 10.4103/0970-9290.123382. PMID: 24355961.
Murray B, Biagioni PA, Lamey PJ. The efficacy of amlexanoxOraDisc on the prevention of recurrent minor aphthous ulceration. J Oral Pathol Med. 2006 Feb;35(2):117-22. doi: 10.1111/j.1600-0714.2006.00379.x. PMID: 16430743.
Meng W, Dong Y, Liu J, Wang Z, Zhong X, Chen R, Zhou H, Lin M, Jiang L, Gao F, Xu T, Chen Q, Zeng X. A clinical evaluation of amlexanox oral adhesive pellicles in the treatment of recurrent aphthous stomatitis and comparison with amlexanox oral tablets: a randomized, placebo controlled, blinded, multicenter clinical trial. Trials. 2009 May 6;10:30. doi: 10.1186/1745-6215-10-30. PMID: 19419555; PMCID: PMC2690593.
Darshan DD, Kumar CN, Kumar AD, Manikantan NS, Balakrishnan D, Uthkal MP. Clinical study to know the efficacy of Amlexanox 5% with other topical Antiseptic, Analgesic and Anesthetic agents in treating minor RAS. J Int Oral Health. 2014 Feb;6(1):5-11. Epub 2014 Feb 26. PMID: 24653596; PMCID: PMC3959130.
Greer RO Jr, Lindenmuth JE, Juarez T, Khandwala A. A double-blind study of topically applied 5% amlexanox in the treatment of aphthous ulcers. J Oral Maxillofac Surg. 1993 Mar;51(3):243-8; discussion 248-9. doi: 10.1016/s0278-2391(10)80164-8. PMID: 8445464.
Bell J. Amlexanox for the treatment of recurrent aphthous ulcers. Clin Drug Investig. 2005;25(9):555-66. doi: 10.2165/00044011-200525090-00001. PMID: 17532700.
Binnie WH, Curro FA, Khandwala A, Van Inwegan RG. Amlexanox oral paste: a novel treatment that accelerates the healing of aphthous ulcers. Compend Contin Educ Dent. 1997 Nov;18(11):1116-8, 1120-2, 1124 passim. PMID: 9533345.
At the age of 60, I look and feel better than I ever have in my entire life! Switching my health program and hormone replacement therapy regimen over to Genemedics was one of the best decisions I’ve ever made in my life! Genemedics and Dr George have significantly improved my quality of life and also dramatically improved my overall health. I hav...
Nick Cassavetes ,60 yrs old Movie Director (“The Notebook”, “John Q”, “Alpha Dog”), Actor and Writer
I am now in my mid-sixties and feel better than I did in my 20’s. Many people have commented that I actually look 20 years younger since I started the program at Genemedics.
Calling Dr. George has proven to be one of the best decisions I have made in my life. Doctors and society convince us that developing various health issues and negative sy...
Pamela Hill ,66 yrs old
Call 800-277-4041 for a Free Consultation
Genemedics® Health Institute is a global premier institute dedicated to revolutionizing health and medicine through healthy lifestyle education, guidance and accountability in harmony with functional medicine. Our physician-supervised health programs are personally customized to help you reach your health and fitness goals while looking and feeling better than ever.
STEPS AWAY FROM A YOUNGER. HEALTHIER YOU!
Call 800-277-4041 for a Free Consultation
What to expect during your consultation: